Research programme: anti CSF1R monoclonal antibody - Adagene/Guilin Sanjin Pharmaceutical
Latest Information Update: 28 Jan 2023
At a glance
- Originator Adagene
- Developer Adagene; Guilin Sanjin Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Colony-stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer